Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Switching From Arixtra (Fondaparinux) to Angiomax (Bivalirudin) or Unfractionated Heparin in Patients With Acute Coronary Syndromes (ACS) Without ST-segment Elevation Undergoing Percutaneous Coronary Intervention (PCI): SWITCH III

NCT00464087 is registered in ClinicalTrials.gov with Medstar Health Research Institute as lead sponsor.

NCT NCT00464087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00464087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Switching From Arixtra (Fondaparinux) to Angiomax (Bivalirudin) or Unfractionated Heparin in Patients With Acute Coronary Syndromes (ACS) Without ST-segment Elevation Undergoing Percutaneous Coronary Intervention (PCI): SWITCH III
Lead sponsor
Medstar Health Research Institute
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2007
Completion date
November 30, 2010
Enrollment
100 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndromes